Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Watkinson

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Health Services Management|May 8, 1993
Contracting models for purchasingT Watkinson
The Canadian Journal of Cardiology|November 1, 2015
A Family History of Sudden Death Should Not Be a Primary Indication for an Implantable Cardioverter Defibrillator in Hypertrophic CardiomyopathyOliver T Watkinson, Perry M Elliott
Clinical Biomechanics (Bristol, Avon)|August 7, 2013
A description of normal relaxed standing posturesM D D'Angelo, D W Grieve, L Fernandez Pereira, et al.
Frontiers in Immunology|November 26, 2025
Case Report: A simple case of drug-induced secondary antibody deficiency or a rare primary immune deficiency?Sarah L Johnston, Julie C Evans, Ian R Berry, et al.
Journal of the American Society of Nephrology : JASN|December 17, 2016
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter StudyMaarten Arends, Christoph Wanner, Derralynn Hughes, et al.
Plos One|August 2, 2017
Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factorsMaarten Arends, Marieke Biegstraaten, Derralynn A Hughes, et al.
JAMA Cardiology|February 7, 2019
Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical TrialCaroline J Coats, Menelaos Pavlou, Oliver T Watkinson, et al.
Journal of Medical Genetics|February 14, 2018
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort studyMaarten Arends, Marieke Biegstraaten, Christoph Wanner, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Health Services Management|May 8, 1993
Contracting models for purchasingT Watkinson
The Canadian Journal of Cardiology|November 1, 2015
A Family History of Sudden Death Should Not Be a Primary Indication for an Implantable Cardioverter Defibrillator in Hypertrophic CardiomyopathyOliver T Watkinson, Perry M Elliott
Clinical Biomechanics (Bristol, Avon)|August 7, 2013
A description of normal relaxed standing posturesM D D'Angelo, D W Grieve, L Fernandez Pereira, et al.
Frontiers in Immunology|November 26, 2025
Case Report: A simple case of drug-induced secondary antibody deficiency or a rare primary immune deficiency?Sarah L Johnston, Julie C Evans, Ian R Berry, et al.
Journal of the American Society of Nephrology : JASN|December 17, 2016
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter StudyMaarten Arends, Christoph Wanner, Derralynn Hughes, et al.
Plos One|August 2, 2017
Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factorsMaarten Arends, Marieke Biegstraaten, Derralynn A Hughes, et al.
JAMA Cardiology|February 7, 2019
Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical TrialCaroline J Coats, Menelaos Pavlou, Oliver T Watkinson, et al.
Journal of Medical Genetics|February 14, 2018
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort studyMaarten Arends, Marieke Biegstraaten, Christoph Wanner, et al.
Pageof 1